Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy Chataway

Showing results (81-90 of 182) with videos related to

Pageof 19
Sort By:
Plos One|March 19, 2015
A predictive model for corticosteroid response in individual patients with MS relapsesMartin Rakusa, Stefan J Cano, Bernadette Porter, et al.
Brain and Behavior|August 4, 2022
The prognostic significance of early blood neurofilament light chain concentration and magnetic resonance imaging variables in relapse-onset multiple sclerosisThomas Williams, Amanda Heslegrave, Henrik Zetterberg, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 16, 2025
Comparative Responsiveness of Preference-Based Health-Related Quality of Life, Social Care, and Well-Being Measures in the Context of Multiple SclerosisElizabeth Goodwin, Amy Heather, Nia Morrish, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 28, 2010
A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosisJeremy Chataway, Richard Nicholas, Susan Todd, et al.
Brain Connectivity|August 12, 2021
A Systematic Review of Resting-State Functional MRI Connectivity Changes and Cognitive Impairment in Multiple SclerosisDanka Jandric, Anisha Doshi, Richelle Scott, et al.
Multiple Sclerosis and Related Disorders|June 7, 2022
Efficacy of Fluoxetine, Riluzole and Amiloride in treating neuropathic pain associated with secondary progressive multiple sclerosis. Pre-specified analysis of the MS-SMART double-blind randomised placebo-controlled trialPeter Foley, Richard A Parker, Floriana de Angelis, et al.
Multiple Sclerosis and Related Disorders|January 10, 2019
Therapeutic lag in reducing disability progression in relapsing-remitting multiple sclerosis: 8-year follow-up of two randomized add-on trials with atorvastatinRoberta Lanzillo, Marcello Moccia, Cinzia Valeria Russo, et al.
Lancet (London, England)|May 28, 2026
Multi-arm multi-stage platform trials for neurological disease: accelerating progressParesh Malhotra, Suvankar Pal, Emma Tallantyre, et al.
The Lancet. Neurology|June 11, 2017
Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trialDennis Chan, Sophie Binks, Jennifer M Nicholas, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 10, 2022
Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trialThomas Williams, Carmen Tur, Arman Eshaghi, et al.
Pageof 19

Showing results (81-90 of 182) with videos related to

Sort By:
Pageof 19
Plos One|March 19, 2015
A predictive model for corticosteroid response in individual patients with MS relapsesMartin Rakusa, Stefan J Cano, Bernadette Porter, et al.
Brain and Behavior|August 4, 2022
The prognostic significance of early blood neurofilament light chain concentration and magnetic resonance imaging variables in relapse-onset multiple sclerosisThomas Williams, Amanda Heslegrave, Henrik Zetterberg, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 16, 2025
Comparative Responsiveness of Preference-Based Health-Related Quality of Life, Social Care, and Well-Being Measures in the Context of Multiple SclerosisElizabeth Goodwin, Amy Heather, Nia Morrish, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 28, 2010
A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosisJeremy Chataway, Richard Nicholas, Susan Todd, et al.
Brain Connectivity|August 12, 2021
A Systematic Review of Resting-State Functional MRI Connectivity Changes and Cognitive Impairment in Multiple SclerosisDanka Jandric, Anisha Doshi, Richelle Scott, et al.
Multiple Sclerosis and Related Disorders|June 7, 2022
Efficacy of Fluoxetine, Riluzole and Amiloride in treating neuropathic pain associated with secondary progressive multiple sclerosis. Pre-specified analysis of the MS-SMART double-blind randomised placebo-controlled trialPeter Foley, Richard A Parker, Floriana de Angelis, et al.
Multiple Sclerosis and Related Disorders|January 10, 2019
Therapeutic lag in reducing disability progression in relapsing-remitting multiple sclerosis: 8-year follow-up of two randomized add-on trials with atorvastatinRoberta Lanzillo, Marcello Moccia, Cinzia Valeria Russo, et al.
Lancet (London, England)|May 28, 2026
Multi-arm multi-stage platform trials for neurological disease: accelerating progressParesh Malhotra, Suvankar Pal, Emma Tallantyre, et al.
The Lancet. Neurology|June 11, 2017
Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trialDennis Chan, Sophie Binks, Jennifer M Nicholas, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 10, 2022
Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trialThomas Williams, Carmen Tur, Arman Eshaghi, et al.
Pageof 19